TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Weich, Alexander
A1  - Higuchi, Takahiro
A1  - Schmid, Jan S.
A1  - Schirbel, Andreas
A1  - Lassmann, Michael
A1  - Wild, Vanessa
A1  - Rudelius, Martina
A1  - Kudlich, Theodor
A1  - Herrmann, Ken
A1  - Scheurlen, Michael
A1  - Buck, Andreas K.
A1  - Kropf, Saskia
A1  - Wester, Hans-Jürgen
A1  - Lapa, Constantin
T1  - Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
JF  - Theranostics
N2  - C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [\(^{68}\)Ga]Pentixafor in comparison to \(^{68}\)Ga-DOTA-D-Phe-Tyr3-octreotide ([\(^{68}\)Ga]DOTATOC) and \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [\(^{68}\)Ga]DOTATOC, [\(^{18}\)F]FDG, and [\(^{68}\)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [\(^{68}\)Ga]Pentixafor visualized tumor lesions in 6/12 subjects, whereas [\(^{18}\)F]FDG revealed sites of disease in 10/12 and [\(^{68}\)Ga]DOTATOC in 11/12 patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited [\(^{68}\)Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor grade. Thus, [\(^{68}\)Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.
KW  - SSTR
KW  - peptide receptor radionuclide therapy
KW  - neuroendocrine tumor
KW  - [\(^{68}\)Ga]Pentixafor
KW  - CXCR4
KW  - chemokine receptor
KW  - PET/CT
KW  - DOTATOC
KW  - PRRT
KW  - Positronen-Emissions-Tomografie
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158008
VL  - 7
IS  - 6
ER  - 
TY  - JOUR
A1  - Bothe, Katrin
A1  - Aguzzi, Adriano
A1  - Lassmann, Hans
A1  - Rethwilm, Axel
A1  - Horak, Ivan
T1  - Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes
N2  - Transgenie mice carrying the bel region of human foamy retrovirus (HFV) under transcriptional control of its own long terminal repeat expressed tbe transgene in their centrat nervous systems and in smootb and striated muscle tissues. The animals developed a progressive degenerative disease of tbe centrat nervous system and of the striated muscle. Because expression of tbe transgene was dosely correlated witb the appearance of structural damage and inflammatory reactions were scanty, the disease is likely to be caused directly by tbe HFV proteins. These unexpected findings call for a reevaluation of tbe patbogenic potential of HFV in humans.
KW  - Virologie
Y1  - 1991
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-61453
ER  - 
TY  - JOUR
A1  - Wester, Hans Jürgen
A1  - Keller, Ulrich
A1  - Schottelius, Margret
A1  - Beer, Ambros
A1  - Philipp-Abbrederis, Kathrin
A1  - Hoffmann, Frauke
A1  - Šimeček, Jakub
A1  - Gerngross, Carlos
A1  - Lassmann, Michael
A1  - Herrmann, Ken
A1  - Pellegata, Natalia
A1  - Rudelius, Martina
A1  - Kessler, Horst
A1  - Schwaiger, Markus
T1  - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
JF  - Theranostics
N2  - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
KW  - acute myeloid leukemia
KW  - prognostic value
KW  - therapeutic target
KW  - chemokine receptor
KW  - CXCR4
KW  - lymphoma
KW  - in vivo imaging
KW  - positron emission tomography
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144537
VL  - 5
IS  - 6
ER  -